Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer

Annals of Oncology

Volumn 19, Issue 2, 2008, Pages 348-352

  de Geus Oei, L F ^a   van Laarhoven, H W M ^a   Visser, E P ^a   Hermsen, R ^a   van Hoorn, B A ^a   Kamm, Y J L ^a   Krabbe, P F M ^a   Corstens, F H M ^a   Punt, C J A ^a   Oyen, W J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy response monitoring; Colorectal cancer; F 18 fluorodeoxyglucose positron emission tomography (FDG PET); Patlak analysis (MRGlu); Standardized uptake value (SUV)

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; GLUCOSE; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; EARLY INTERVENTION; FEMALE; FOLLOW UP; GLUCOSE METABOLISM; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLIC RATE; OVERALL SURVIVAL; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; QUANTITATIVE ANALYSIS; REGRESSION ANALYSIS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EVALUATION STUDIES AS TOPIC; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 38849118300     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm470     Document Type: Article

References (31)

1. Even-Sapir E, Parag Y, Lerman H et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 2004; 232: 815-822.
2. Bipat S, van Leeuwen MS, Comans EF et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis - meta-analysis. Radiology 2005; 237: 123-131.
3. Kinkel K, Lu Y, Both M et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): A meta-analysis. Radiology 2002; 224: 748-756.
4. Wiering E, Krabbe PF, Jager GJ et al. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005; 104: 2658-2670.
5. Flamen P, Hoekstra OS, Homans F et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: The utility of positron emission tomography (PET). Eur J Cancer 2001; 37: 862-869.
6. Ito K, Kato T, Tadokoro M et al. Recurrent rectal cancer and scar: differentiation with PET and MR imaging. Radiology 1992; 182: 549-552.
7. Votrubova J, Belohlavek O, Jaruskuva M et al. The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Moll Imaging 2006; 33: 779-784.
8. Ruers TJ, Langenhoff BS, Neeleman N et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: A prospective study. J Clin Oncol 2002; 20: 388-395.
9. Pauwels EK, McCready VR, Stoot JH et al. The mechanism of accumulation of tumour-localising radiopharmaceuticals. Eur J Nucl Med 1998; 25: 277-305.
10. de Geus-Oei LF, Visser EP, Krabbe PF et al. Comparison of image-derived and arterial input functions for estmating the rate of glucose metabolism in therapy-monitoring 18F-FDG PET studies. J Nucl Med 2006; 47: 945-949.
11. Greuter HN, Boellaard R, van Lingen A et al. Measurement of 18F-FDG concentrations in blood samples: Comparison of direct calibration and standard solution methods. J Nucl Med Technol 2003; 31: 206-209.
12. Patlak CS, Blasberg FIG, Fenstermacher A Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3: 1-7.
13. Hoekstra CJ, Hoekstra OS, Stroobants SG et al. Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med 2002; 43: 1304-1309.
14. Young H, Baum R, Cremerius U et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose: And positron emission tomography: Review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC). PET Study Group. Eur J Cancer 1999; 35: 1773-1782.
15. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
16. Westerterp M, Pruim J, Oyen W et al. Quantification of FOG PET studies using, standardised uptake values in multi-centre trials: Effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging 2007; 34: 392-404.
17. Amthauer H, Denecke T, Rau B et al. Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hypenthermia of rectal cancer: Correlation with endorectal ultrasound and histopathology. Eur J Nucl Med Mol Imaging 2004; 31: 811-819.
18. Denecke T, Rau B, Hoffmann KT et al. Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: Is there a benefit in using functional imaging? Eur Radiol 2005; 15: 1658-1666.
19. Guillem JG, Puig-La CJ Jr, Akhurst T et al. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 2000; 43: 18-24.
20. Guillem JG, Moore HG, Akhurst T et al. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: A means for determining longterm outcomes of rectal cancer. J Am Coll Surg 2004; 199: 1-7.
21. Calvo FA, Domper W, Matute R et al, 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2004; 58: 528-535.
22. Schiepers G, Haustermans K, Geboes K et al. The effect of preoperative radiation therapy on glucose utilization and cell kinetics in patients with primary rectal carcinoma. Cancer 1999; 85: 803-811.
23. Cascini GL, Avallone A, Delrio P et al. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med 2006; 47: 1241-1248.
24. Langenhoff BS, Oyen WJ, Jager GJ et al. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: A prospecfive study. J Clin Oncol 2002; 20: 4453-4458.
25. Joosten J, Jager G, Oyen W et al. Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases. Eur J Surg Oncol 2005; 31: 1152-1159.
26. Donckier V, Van Laethem JL, Goldman S et al. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol 2003; 84: 215-223.
27. Blokhuis TJ, van der Schaaf MC, van den Tol MP et al. Results of radio frequency ablation of primary and secondary liver tumors: Long-term follow-up with computed tomography and positron emission tomography-18F-deoxyfluoroglucose scanning. Scand J Gastroenterol Suppl 2004: 93-97.
28. Findlay M, Young H, Cunningham D et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil. J Clin Oncol 1996; 14: 700-708.
29. Bender H, Bangard N, Metten N et al. Possible role of FDG-PET in the early predicton of therapy-outcome in liver metastases of colorectal cancer. Hybridoma 1999; 18: & 87-91.
30. Dimitrakopoulou-Strauss A, Strauss LG, Rudi J. PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Q J Nucl Med 2003; 47: 8-13.
31. Dimitrakopoulou-Strauss A, Strauss LG, Burger C et al. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med 2004; 45: 1480-1487.